SNY earnings call for the period ending March 31, 2019.
News & Analysis: Sanofi
American regulators rejected a type 1 diabetes treatment that analysts predicted would eventually eclipse $450 million in annual revenue.
Novavax's experimental flu vaccine hits the mark in a highly anticipated midstage trial.
SNY earnings call for the period ending September 30, 2018.
This special kind of security is highly speculative and very rare.
These buy-and-hold dividend stocks can be counted on for income.
These three stocks are backed by Buffett and Berkshire and could help power your portfolio to market-beating returns.
More people than ever are being diagnosed with diabetes, and big advances in treatment could make these diabetes stocks savvy investments.
But are these high-yielding stocks in the billionaire investor's portfolio smart picks for the rest of us?
Here's an international healthcare stock to consider for your portfolio.